Azenta Life Sciences expands fleet of PacBio HiFi sequencing systems
PacBio’s Sequel IIe devices will support genomic researchers around the world
7 Jan 2022
PacBio has announced an expansion of its extensive suite of HiFi applications with Azenta Life Sciences, formerly GENEWIZ. The deal will increase PacBio’s HiFi sequencing platforms across Azenta’s newly combined company and support Azenta’s mission to enable life science companies to deliver impactful breakthroughs and therapies to market faster.
PacBio’s HiFi sequencing technology uniquely combines the benefits of high accuracy with long read lengths, providing a comprehensive view of genomes and transcriptomes to scientists tackling complex genetic challenges. Azenta’s expanded investment in HiFi sequencing signifies the technology’s ability to unlock invaluable insights for researchers in academia, pharma, and biotech.
"Azenta is a global leader in genomics services, and we’re very pleased that our highly accurate HiFi sequencing technology will continue to underpin leading-edge research to build a healthier world for people everywhere," said Christian Henry, CEO at PacBio. "With a focus on the future, we are continuing to redefine what is possible in genomics."
With more than 20 years of experience specializing in DNA and RNA sequencing and synthesis services, working with over 6,000 institutions worldwide, Azenta is using PacBio Sequel IIe technology to offer enterprise-wide sample exploration and management solutions across the drug development pipeline.
"We are excited to significantly increase our capacity by offering a best-in-class long-read sequencing platform supporting customers through our unique solutions spanning broad genomics applications," said Ginger Zhou, vice president and general manager at Azenta Life Sciences. "The new Sequel IIe platform, in combination with our team of scientific experts, will enable our diverse customer base to obtain actionable data faster."
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Related Products
Request Quote for All Products
Sequel System
Pacific BiosciencesThe new Sequel System is based on Pacific Bioscience’s proven Single Molecule, Real-Time (SMRT) technology and delivers about 7X more reads with 1 million zero-mode waveguides (ZMWs) per SMRT Cell. The Sequel System is ideal for projects such as rapidly and cost-effectively generating high-quality whole genome de novo assemblies. This innovative sequencing system features automated reagent and SMRT Cell handling and an integrated software suite. The Sequel System has two primary user access points: Sequel touchscreen interface (for initiating and monitoring runs) Sequel workdeck (for loading samples, SMRT Cells, reagents, and disposables) Features: Intuitive run setup and monitoring tools Run-time flexibility (from 30 minutes to 6 hours per SMRT Cell) Run-size flexibility (from 1 to 16 SMRT Cells per run) Robotic workflow management
PACBIO RS II
Pacific BiosciencesThe PacBio RS II is a Single Molecule, Real-Time (SMRT®) DNA Sequencing System that provides the highest consensus accuracy and longest read lengths of any available sequencing technology. SMRT Sequencing is ideal for de novo assembly, characterization of genetic variation, methylation analysis, microbiology studies, and more.The instrument features high performance optics, automated liquid handling, and an environmental control center, all directed through an intuitive touchscreen interface. The computational brain responsible for primary data analysis, called the Blade Center, is also included. This allows for seamless integration of performance enhancements through chemistry and software advances.Features: Intuitive run setup tools Workflow optimization tools Error-proof instrument loading Robotic workflow management Run size flexibility – from 1 to 16 SMRT Cells per run Applications: Genome finishing Epigenetics Haplotype phasing Repeat expansions Isoform sequencing Minor variants